[go: up one dir, main page]

ECSP13012959A - Composicion de complejo oral que contiene ester de acido graso omega-3 e inhibidor de reductasa hmg-coa - Google Patents

Composicion de complejo oral que contiene ester de acido graso omega-3 e inhibidor de reductasa hmg-coa

Info

Publication number
ECSP13012959A
ECSP13012959A ECSP13012959A ECSP13012959A EC SP13012959 A ECSP13012959 A EC SP13012959A EC SP13012959 A ECSP13012959 A EC SP13012959A EC SP13012959 A ECSP13012959 A EC SP13012959A
Authority
EC
Ecuador
Prior art keywords
hmg
fatty acid
acid ester
composition containing
coa reductase
Prior art date
Application number
Other languages
English (en)
Inventor
Jong Soo Woo
Jae Hyun Park
Yong Il Kim
Eun Jin Yoon
Ho Taek Im
Yoon Sub Shin
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47280992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012959(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of ECSP13012959A publication Critical patent/ECSP13012959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición de complejo oral que contiene éster de ácido graso omega-3 e inhibidor de la reductasa HMG-CoA puede aumentar en forma efectiva el nivel de lipoproteína de alta densidad y los niveles de triglicéridos, pudiendo ser utilizada para tratar hiperlipidemia, debido a su buen régimen de disolución del medicamento y estabilidad bajo almacenamiento, sin presentar comportamiento de liberación demorada inclusive después de 6 meses de almacenamiento acelerado.
ECSP13012959 2011-03-23 2013-10-09 Composicion de complejo oral que contiene ester de acido graso omega-3 e inhibidor de reductasa hmg-coa ECSP13012959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110025940 2011-03-23
KR1020110041168A KR101310710B1 (ko) 2011-03-23 2011-04-29 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물

Publications (1)

Publication Number Publication Date
ECSP13012959A true ECSP13012959A (es) 2013-11-29

Family

ID=47280992

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012959 ECSP13012959A (es) 2011-03-23 2013-10-09 Composicion de complejo oral que contiene ester de acido graso omega-3 e inhibidor de reductasa hmg-coa

Country Status (31)

Country Link
US (1) US20140010872A1 (es)
EP (1) EP2688558B1 (es)
JP (1) JP2014508802A (es)
KR (1) KR101310710B1 (es)
CN (1) CN103442699B (es)
AR (1) AR085547A1 (es)
AU (1) AU2012231944B2 (es)
BR (1) BR112013023819A2 (es)
CA (1) CA2830342C (es)
CL (1) CL2013002611A1 (es)
CO (1) CO6801750A2 (es)
CR (1) CR20130491A (es)
DO (1) DOP2013000210A (es)
EA (1) EA023405B1 (es)
EC (1) ECSP13012959A (es)
ES (1) ES2550392T3 (es)
GT (1) GT201300217A (es)
IL (1) IL228516A (es)
JO (1) JO3071B1 (es)
MA (1) MA35042B1 (es)
MX (1) MX343097B (es)
MY (1) MY157200A (es)
NI (1) NI201300086A (es)
PE (1) PE20140640A1 (es)
PH (1) PH12013501946A1 (es)
SA (1) SA112330374B1 (es)
SG (1) SG193491A1 (es)
TW (1) TWI571271B (es)
UA (1) UA106457C2 (es)
WO (1) WO2012128587A2 (es)
ZA (1) ZA201307871B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
US20120100208A1 (en) 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US20120093922A1 (en) 2009-04-29 2012-04-19 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG177254A1 (en) 2009-06-15 2012-02-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
PT4342546T (pt) 2012-06-29 2025-09-01 Amarin Pharmaceuticals Ie Ltd Éster etílico do ácido eicosapentanoico para utilização na redução do risco de acidente vascular cerebral não-fatal num indivíduo em terapia com estatina
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) * 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
GB2512098A (en) * 2013-03-20 2014-09-24 Roly Bufton An oral dosage form
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
WO2014182003A1 (en) * 2013-05-06 2014-11-13 Hanmi Pharm. Co., Ltd. Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
PL3150201T3 (pl) * 2014-06-30 2020-09-21 Hanmi Pharm. Co., Ltd. Preparat kompozytowy zawierający błonową warstwę powlekającą zawierającą inhibitor 5-reduktazy i sposób wytwarzania preparatu kompozytowego
BR112016030731A2 (pt) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd Preparação de compósito, e, método de preparação de uma preparação de compósito
MY181172A (en) * 2014-06-30 2020-12-21 Hanmi Pharm Ind Co Ltd Composite preparation comprising active ingredient-containing film coating layer
TWI525110B (zh) * 2014-12-24 2016-03-11 財團法人工業技術研究院 聚合物、及包含其之醫藥組合物
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2017171484A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
DK4056176T3 (da) 2018-09-24 2024-05-06 Amarin Pharmaceuticals Ie Ltd Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
KR20250028769A (ko) 2023-08-22 2025-03-04 한국유나이티드제약 주식회사 지용성 약물 및 스타틴계 약물을 포함하는 복합제
CN119454974A (zh) * 2024-11-28 2025-02-18 中国药科大学 含ω-3脂肪酸及他汀类药物的药物组合物及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
AU3651102A (en) * 2000-11-29 2002-06-11 Smithkline Beecham Corp Composition containing statins and calcium for improved cardiovascular health
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
AU2005314361B2 (en) * 2004-12-06 2012-04-12 Glaxosmithkline Llc Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
CA2600429A1 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceuticals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
JP2009502950A (ja) * 2005-07-28 2009-01-29 レリアント ファーマスーティカルズ インコーポレイテッド ジヒドロピリジンカルシウムチャネルブロッカー及びω３脂肪酸を用いた治療法、並びにそれらの混合生成物
EP2081550B2 (en) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20090041839A1 (en) * 2007-05-23 2009-02-12 Beasley Martin W Pharmaceutical compositions for the treatment of pain
CA2711814A1 (en) * 2008-01-10 2009-07-16 Takeda Pharmaceutical Company Limited Capsule formulation
MX2010008940A (es) * 2008-02-13 2010-10-05 Bayer Schering Pharma Ag Sistemas de administracion de drogas que contienen estradiol.
KR20090091083A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 심혈관계질환 치료용 약제학적 제제
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.

Also Published As

Publication number Publication date
EA023405B1 (ru) 2016-05-31
NI201300086A (es) 2014-05-05
EA201391372A1 (ru) 2014-01-30
JO3071B1 (ar) 2017-03-15
EP2688558B1 (en) 2015-10-14
WO2012128587A3 (en) 2012-11-15
EP2688558A2 (en) 2014-01-29
SA112330374B1 (ar) 2015-01-08
MY157200A (en) 2016-05-13
HK1189173A1 (en) 2014-05-30
NZ616907A (en) 2016-02-26
IL228516A0 (en) 2013-12-31
TW201249483A (en) 2012-12-16
CN103442699B (zh) 2015-07-01
DOP2013000210A (es) 2014-01-31
ZA201307871B (en) 2015-01-28
UA106457C2 (ru) 2014-08-26
CN103442699A (zh) 2013-12-11
SG193491A1 (en) 2013-10-30
JP2014508802A (ja) 2014-04-10
CR20130491A (es) 2013-10-22
GT201300217A (es) 2014-12-30
CA2830342C (en) 2016-01-19
BR112013023819A2 (pt) 2016-12-13
PH12013501946A1 (en) 2014-01-06
MX343097B (es) 2016-10-25
AR085547A1 (es) 2013-10-09
CO6801750A2 (es) 2013-11-29
PE20140640A1 (es) 2014-06-11
IL228516A (en) 2017-12-31
EP2688558A4 (en) 2014-09-24
MA35042B1 (fr) 2014-04-03
US20140010872A1 (en) 2014-01-09
WO2012128587A2 (en) 2012-09-27
AU2012231944B2 (en) 2015-08-27
ES2550392T3 (es) 2015-11-06
TWI571271B (zh) 2017-02-21
CA2830342A1 (en) 2012-09-27
MX2013010753A (es) 2013-10-17
KR101310710B1 (ko) 2013-09-27
KR20120109950A (ko) 2012-10-09
AU2012231944A1 (en) 2013-05-02
CL2013002611A1 (es) 2014-07-11

Similar Documents

Publication Publication Date Title
ECSP13012959A (es) Composicion de complejo oral que contiene ester de acido graso omega-3 e inhibidor de reductasa hmg-coa
CO7121328A2 (es) Composiciones de ester de ácido graso omega -3
MX2020002907A (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
CL2019003105A1 (es) Lípidos extraídos de plantas que comprenden ácidos grasos poliinsaturados de cadena larga. (divisional solicitud 201601560)
MX2019013171A (es) Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos.
MX2014000770A (es) Composiciones de acidos grasos.
SV2011003798A (es) Salicilatos acetilados con acidos grasos y sus usos
MX2019011333A (es) Composiciones y metodos para el uso de esteres de forbol para el tratamiento de accidentes cerebrovasculares.
AR087254A1 (es) Gliceratos de metales alcalinos y alcalinoterreos para la desacidificacion y secado de esteres de acidos grasos
BR112017008033A2 (pt) composição farmacêutica para administração oral e respectivo processo de preparação
AR098900A1 (es) Composiciones y métodos para el cuidado oral
CR20150281A (es) Proceso de fabricación de biocarburantes
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
UY35445A (es) Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral
UY34455A (es) Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada
AR098772A1 (es) Composiciones para cuidado oral y métodos
CL2023001737A1 (es) Ésteres de ácido dicarboxílico para inducir un efecto analgésico
AR106196A1 (es) Compuestos de antioxidantes estables bajo almacenamiento que contienen ácido ascórbico
ES2524645B1 (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CR20110015A (es) Salicilatos acetilados con acidos grasos y sus usos
CL2010000827A1 (es) Producto alimenticios que es seco y que contiene una formulacion de sal de mesa que comprende una mezcla de al menos dos tipos de particulas de sales inorganicas donde al menos un tipo de dichas particulas el 50% posee un diametro de 5 a 5000 nm; su metodo de elaboracion; y su uso.